Compare peptide results by the problem studied
A peptide can change a blood test, a tendon or a desire score. I resist giving all those changes the same name.
The question each experiment answered
The five compounds share peptide chemistry and very little else about their most persuasive results. The comparison below pairs each one with a concrete outcome. It is a set of different questions rather than a contest with a single winner.
| Compound | Experiment and result | Remaining question |
|---|---|---|
| BPC-157 | Severed rat Achilles tendons recovered better in mechanical and functional tests. | A controlled human repair result. |
| CJC-1295 | Healthy adults had higher GH and IGF-1 for days. | A demonstrated health benefit from those hormonal changes. |
| MOTS-c | Mouse muscle took up more glucose and resisted wasting; CK2 responses differed between muscle and fat. | Benefit and safety when given to people. |
| PT-141 | Desire and distress improved in 1,267 women with HSDD. | How a modest average benefit balances against nausea for an individual. |
| Tirzepatide | Mean weight loss was 20.2% over 72 weeks in SURMOUNT-5. | Tolerability and long-term consequences alongside the weight change. |
I give the tirzepatide weight evidence much more credit than the BPC-157 human repair evidence. That judgement says nothing about substituting one for the other. The original problems differ.
Human exposure and approval
Direct human intervention ranges from a two-adult BPC-157 safety pilot to a 2,539-participant tirzepatide obesity trial. BPC-157 also has other small pilots, counted in the 2025 review. CJC-1295 has early human pharmacology studies, including the protein-marker study in eleven men. The MOTS-c cohort of 94 people receiving dialysis measured natural peptide levels and gave no treatment.
PT-141 and tirzepatide have FDA-approved prescription formulations for defined indications. PT-141's approved bremelanotide population is premenopausal women with acquired, generalised HSDD. Tirzepatide covers type 2 diabetes, chronic weight care and moderate to severe sleep apnoea in adults with obesity, within the relevant label conditions.
BPC-157, CJC-1295 and MOTS-c have no FDA approval. BPC-157's withdrawn compounding nomination does not authorize compounding, and FDA safety concerns remain noted. Laboratory stock and a clinician's prescribing decision also involve different questions. I would give neither a laboratory label nor the fact of access the job of proving a treatment benefit.
Several kinds of unfinished business
For BPC-157 and MOTS-c, the most consequential uncertainty is how promising animal biology will behave in people. For CJC-1295, investigators have demonstrated a human hormone response while leaving long-term health outcomes largely unanswered.
With PT-141, the extension study makes nausea difficult to overlook. With tirzepatide, the gallbladder and biliary analysis adds a specific risk signal to large efficacy results. Knowledge of a harm can grow with the amount of testing. Sparse reporting offers much less reassurance than a small table of side effects suggests.
Community reports about repair, sleep, desire or food noise are anecdotal accounts rather than clinical evidence. They can describe experiences worth investigating. They cannot make these separate compounds into interchangeable solutions.